Plain-language overview
Fibrosis is more complicated than simply having 'too much scar tissue.' Normal healing requires fibroblasts, collagen, and temporary scar formation. Problems arise when these repair processes remain excessive, disorganized, or persistent.
MSCs and extracellular vesicles may influence fibroblasts, myofibroblasts, collagen production, matrix-degrading enzymes, and scar remodeling in experimental systems.
The goal of an antifibrotic treatment should not be to eliminate normal repair. It should help restore an appropriate amount and organization of extracellular matrix while preserving tissue strength and organ function.
Fibroblast activity
Fibroblast activity is essential to wound healing. A fibroblast produces extracellular matrix, communicates with immune and vascular cells, and helps restore tissue structure after injury.
MSCs and EV-associated signals may change fibroblast growth, movement, inflammatory signaling, and matrix production in laboratory and animal models.
Reducing fibroblast activity is not automatically beneficial. Too little fibroblast function can interfere with normal healing, while excessive or persistent activity can contribute to fibrosis.
Figure 1 placeholder — Fibroblast activity
Myofibroblast differentiation
Myofibroblast differentiation occurs when fibroblasts or related cells develop a more contractile and matrix-producing state. A myofibroblast helps close wounds but can contribute to fibrosis when it remains activated.
Transforming growth factor-beta is an important profibrotic signal. Mechanical tension and signaling through an integrin can also contribute. Researchers often measure alpha-smooth-muscle actin as one marker of myofibroblast behavior.
A change in one marker does not prove that fibrosis has improved. The effect on tissue structure, mechanics, and function also matters.
Figure 2 placeholder — Myofibroblast differentiation
Collagen deposition
Collagen deposition is necessary for repairing damaged tissue. Collagen provides structural support while a wound heals.
Problems can develop when too much collagen accumulates or when collagen fibers become abnormally organized. Collagen cross-linking, matrix organization, matrix turnover, and tissue stiffness can be as important as the total amount of collagen.
Lowering collagen is therefore not automatically beneficial. Inadequate collagen can weaken healing tissue, while excessive or poorly organized collagen can impair function.
Figure 3 placeholder — Collagen deposition
Matrix metalloproteinases
Matrix metalloproteinases are enzymes that break down components of the extracellular matrix. A matrix metalloproteinase works within a larger system that also includes a tissue inhibitor of metalloproteinases.
This balance helps control matrix turnover. Increasing matrix breakdown may help remove excessive scar in some situations, but excessive proteolysis can damage healthy matrix and weaken tissue.
Measuring one enzyme without measuring its activity, inhibitors, targets, and effects on tissue gives only a partial picture of remodeling.
Figure 4 placeholder — Matrix metalloproteinases
Scar remodeling
Scar remodeling is the later phase of healing in which repair tissue continues to change. Collagen fibers can be removed, replaced, cross-linked, and realigned while the scar's cellularity, blood supply, and mechanical properties evolve.
Normal wound contraction and the fibroproliferative phase are part of repair. Persistent profibrotic signaling can prevent appropriate resolution and contribute to chronic fibrosis.
Improved scar thickness or collagen appearance can support a remodeling mechanism, but it should not automatically be called regeneration. True regeneration requires meaningful restoration of normal tissue structure and function.
Figure 5 placeholder — Scar remodeling
Organ-specific fibrosis
Organ-specific fibrosis means that fibrosis behaves differently in different tissues. Lung, liver, kidney, heart, skin, and musculoskeletal tissues have different resident cells, matrix composition, blood supply, mechanical forces, and disease processes.
A treatment that changes fibrosis in one organ or experimental model cannot automatically be expected to work the same way in another.
Antifibrotic claims therefore need evidence for the specific product, organ, disease, stage of fibrosis, and clinically meaningful functional outcomes.
Figure 6 placeholder — Organ-specific fibrosis
Prevention is different from reversal
Fibrosis prevention and fibrosis reversal are different therapeutic claims. Preventing excessive scar formation early in an injury may be easier than removing mature, highly cross-linked scar that has been present for years.
An intervention that reduces fibrosis in an early animal model should not automatically be described as capable of reversing established human fibrosis.
Matrix quantity versus matrix quality
Healthy remodeling depends on more than the amount of extracellular matrix. Matrix organization, composition, cross-linking, stiffness, and turnover affect how tissue functions.
A smaller scar can still be mechanically weak or poorly organized. Tensile strength and organ-specific function can therefore be more informative than collagen quantity alone.
Potency assays and biomarkers
An antifibrotic effect may be studied with laboratory assays that measure fibroblast behavior, TGF-beta responses, collagen production, or matrix degradation.
A fibrosis biomarker can help researchers follow a biological process, but biomarkers and laboratory potency tests do not replace measurements of organ function or patient outcomes.
Safety and the therapeutic window
Normal healing requires fibroblasts, collagen, and matrix remodeling. Excessively suppressing these processes could impair wound healing, tissue strength, or normal repair.
An antifibrotic treatment therefore needs an appropriate therapeutic window: enough activity to reduce harmful fibrosis without preventing necessary healing.
Questions patients should ask
Is the treatment intended to prevent fibrosis or reverse established fibrosis? Has it been studied in this specific organ and disease? Does the evidence measure only collagen or biomarkers, or does it show improved tissue and organ function? How mature was the fibrosis being treated? What product and dose were studied? Could the proposed antifibrotic effect interfere with normal wound healing?
Bottom line
Fibrosis is a dynamic disorder of tissue repair, not simply an excess of collagen.
Strong evidence distinguishes normal healing from pathological fibrosis, prevention from reversal, and laboratory biomarkers from meaningful organ function. Any claimed antifibrotic effect should be demonstrated for the exact product and the specific fibrotic disease.
How this review was prepared
This Patient Edition was derived directly from the explicitly approved 0705 Professional Edition and preserves the same six controlling Points.